Clinical bottom line
Refractory interstitial lung disease (ILD) associated with idiopathic inflammatory myopathies (IIM) remains a significant cause of morbidity and mortality. Emerging evidence supports the cautious use of novel therapies including rituximab, antifibrotics such as nintedanib, and calcineurin inhibitors like tacrolimus in select patients who fail conventional immunosuppression. While these agents show promise in stabilizing or improving lung function, data remain limited by small cohorts and heterogeneous study designs. Clinicians should individualize treatment decisions, balancing potential benefits against safety profiles and patient-specific factors.
What the evidence shows
Recent studies highlight rituximab as a potentially effective option for refractory IIM-associated ILD. Jang et al. (2023) reported improved lung function trajectories and stabilization of forced vital capacity (FVC) in patients treated with rituximab, with a favorable safety profile in a case series and conference abstract. These findings suggest B-cell depletion may modulate disease activity in this subgroup.
Antifibrotic therapy, particularly nintedanib, has gained attention for its role in progressive fibrosing ILD phenotypes. Wilfong et al. (2021) reviewed the application of antifibrotics in IIM-ILD, noting that nintedanib slowed decline in lung function in clinical trials of fibrosing ILDs, including connective tissue disease-associated ILD. Liang et al. (2020) provided early data on nintedanib’s tolerability and efficacy specifically in IIM-ILD, supporting its use as adjunctive therapy in refractory cases.
Calcineurin inhibitors, especially tacrolimus, have demonstrated efficacy in IIM-ILD management. Gordon et al. (2014) identified tacrolimus responders and defined its role in stabilizing lung disease, particularly when combined with corticosteroids and other immunosuppressants. This agent remains a cornerstone in many treatment algorithms.
Quantitative thoracic imaging advances, as described by Qiang et al. (2025), offer improved phenotypic stratification and monitoring of IIM-ILD subtypes, potentially guiding therapeutic choices and assessing response to novel agents.
Poirier-Blanchette et al. (2026) provide a comprehensive review of novel therapies for refractory IIM-ILD, emphasizing the need for further controlled studies to validate efficacy and safety while highlighting current clinical experience with these agents.
Caveats and uncertainty
Most evidence derives from observational studies, case series, and small trials with heterogeneous patient populations and variable definitions of refractory disease. Randomized controlled trials specifically targeting IIM-ILD are scarce, limiting definitive conclusions on comparative efficacy.
Safety data, particularly long-term, remain incomplete. Rituximab’s immunosuppressive effects raise infection risk concerns, and antifibrotics can cause gastrointestinal and hepatic adverse events. Tacrolimus requires monitoring for nephrotoxicity and neurotoxicity.
Heterogeneity in IIM subtypes, ILD patterns, and disease severity complicates generalizability. Biomarkers predicting response to these novel therapies are under investigation but not yet established in clinical practice.
Imaging modalities and quantitative assessments, while promising, require standardization and validation before routine integration into treatment algorithms.
How this may change practice
Clinicians managing refractory IIM-ILD should consider integrating rituximab and antifibrotic agents like nintedanib into treatment regimens, especially for patients with progressive fibrosing phenotypes unresponsive to conventional immunosuppression. Tacrolimus remains a valuable option, particularly in combination therapy.
Multidisciplinary collaboration involving rheumatology, pulmonology, and radiology is essential to optimize diagnosis, monitoring, and therapeutic decisions. Quantitative imaging may enhance personalized treatment approaches as evidence evolves.
Given current limitations, treatment should be individualized, with careful assessment of risks and benefits, and patients should be counseled on the experimental nature of some therapies. Enrollment in clinical trials is encouraged to advance evidence.